Back to Search Start Over

Merck's Mavenclad gets EU approval as a treatment for MS

Source :
M2 Pharma. August 25, 2017
Publication Year :
2017

Abstract

M2 PHARMA-August 25, 2017-Merck's Mavenclad gets EU approval as a treatment for MS (C)2017 M2 COMMUNICATIONS The European Commission (EC) has approved Merck Group's Mavenclad (cladribine) as a treatment for [...]

Subjects

Subjects :
Multiple sclerosis -- Care and treatment
Cladribine
Drug approval
Chemistry
European Union
European Union. European Commission
Mavenclad (Medication)

Details

Language :
English
Database :
Gale General OneFile
Journal :
M2 Pharma
Publication Type :
News
Accession number :
edsgcl.501720871

Tools

Authors Abstract Subjects Details